Shanghai Biotechnology Corporation (SBC) is a leading biotech company dedicated to advancing human health through innovative research, cutting-edge technologies, and transformative therapies. Founded in 2005, Shanghai Biotechnology Corporation has rapidly evolved into one of China's most respected biotechnology companies. Headquartered in Shanghai's Zhangjiang Hi-Tech Parkoften referred to as China's Silicon Valley of biotechnologySBC has established itself as a pioneer in genomic research, therapeutic development, and precision medicine. Our mission is to develop breakthrough treatments for some of the world's most challenging diseases while making innovative biotechnology accessible to patients globally. With a team of over 1,200 scientists, researchers, and professionals, we are committed to pushing the boundaries of scientific discovery. SBC has invested more than $1.5 billion in R&D infrastructure and capabilities, creating state-of-the-art laboratories, genomic sequencing facilities, and biomanufacturing plants that meet international GMP standards. Our research focuses on four key therapeutic areas that address significant unmet medical needs. SBC's oncology division is developing targeted therapies and immunotherapies for various cancers. Our CAR-T cell therapy program has shown promising results in clinical trials for hematological malignancies, while our small molecule inhibitors are advancing through preclinical development for solid tumors. We leverage molecular profiling to identify genetic drivers of cancer and develop personalized treatment approaches that maximize efficacy while minimizing side effects. Our neurology program focuses on neurodegenerative diseases including Alzheimer's, Parkinson's, and ALS. We're developing disease-modifying therapies that target underlying pathological processes rather than just symptomatic relief. Using advanced protein engineering and gene delivery systems, our neurology team is tackling the blood-brain barrier challenge to deliver therapeutic agents directly to affected neural tissues. SBC is developing next-generation treatments for cardiovascular conditions including heart failure, arrhythmias, and lipid disorders. Our novel biologics target inflammatory pathways implicated in atherosclerosis and other cardiovascular diseases. In metabolic diseases, we're focusing on innovative approaches to treat obesity, diabetes, and non-alcoholic fatty liver disease through mechanisms that improve metabolic function at the cellular level. Building on our rapid response to the COVID-19 pandemic, SBC continues to expand its infectious disease portfolio. Our antiviral candidates target a range of viral pathogens, while our vaccine platform technology enables rapid development against emerging threats. We're also exploring novel antimicrobial approaches to combat antibiotic-resistant bacteria, representing a critical need in global healthcare. Our diversified portfolio includes market-leading products and innovative services. Our approved products include: We have 12 additional candidates in various stages of clinical development, with our most advanced program expected to enter Phase 3 trials in 2024. SBC Diagnostic Services offers comprehensive genomic and proteomic testing: Our CLIA-certified laboratory processes over 50,000 samples annually for hospitals and research institutions worldwide. We partner with pharmaceutical companies and academic institutions to accelerate drug discovery: Our research facilities offer GLP-compliant study conduct with experienced scientific teams specializing in multiple therapeutic areas. SBC operates three state-of-the-art manufacturing facilities with capabilities including: Our facilities are FDA-inspected and EU GMP-approved, allowing us to serve global markets with the highest quality standards. Collaboration is at the heart of our approach to innovation and global impact. SBC has established partnerships with leading pharmaceutical companies, biotechnology firms, and academic institutions worldwide. These alliances allow us to combine our scientific expertise with complementary capabilities to accelerate the development of innovative therapies. Our current partnerships include joint development agreements, technology licensing arrangements, and strategic investments that strengthen our ability to deliver breakthrough treatments to patients globally. PharmaCorp USA EuroBiotech Japan MedSci Cambridge Institute Karolinska Lab Singapore Bio Our leadership team combines decades of experience in biotechnology, healthcare, and business. Chief Executive Officer Former Chairman of Peking University's Department of Molecular Biology with over 30 years of experience in biotechnology research and development. Chief Scientific Officer Previously with Genentech and Amgen, Dr. Johnson brings extensive experience in oncology drug discovery and clinical development. Chief Financial Officer Former VP of Finance at Medtronic Asia, with background in strategic planning, mergers and acquisitions, and capital markets. Chief Medical Officer Former Clinical Development Director at Takeda Oncology with expertise in global clinical trial design and regulatory strategy. Chief Operating Officer 20+ years of operations experience in biotechnology manufacturing, previously COO of BioMarin's Asian operations. Chief Business Officer Former VP of Business Development at Samsung Biologics with extensive experience in deal-making and partnerships in Asia and globally. 500 Zhangjiang Road, Zhangjiang Hi-Tech Park +86 21 5080 8888 info@shanghaibiotech.com www.shanghaibiotech.comPioneering the Future of Biotechnology in Asia
About SBC
Transforming Healthcare Through Innovation
Research & Development
Products & Services
Therapeutic Products
Diagnostic Services
Research Services
Biopharmaceutical Manufacturing
Global Partnerships
Strategic Alliances
Key International Partners
Leadership Team
Dr. Li Wei
Dr. Sarah Johnson
Michael Chen
Dr. Yuki Tanaka
Elena Rodriguez
David Park
Contact Us
Get In Touch
Headquarters
Pudong New District, Shanghai 201203, ChinaPhone
Email
Website
Send Us a Message
2022 Shanghai Government Scholarship For International Students Of Fudan University and Re...
